Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Tris Pharma Inc.
WARNING LETTER
•Tris Pharma Inc.•March 20, 2017

Tris Pharma Inc. – FDA Warning Letter, Mar 20, 2017

Record Details

The FDA issued a Warning Letter to Tris Pharma Inc. following a February-March 2017 inspection, citing significant CGMP violations, rendering their drug products adulterated.

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** The firm failed to thoroughly investigate product failures and complaints, lacking root cause analysis and effective CAPA. This was a recurring issue from prior inspections (2011, 2012, 2014). * **Quillivant XR Dissolution Failures:** Five lots failed dissolution testing (release/stability). Investigations improperly invalidated OOS results, blaming the test method instead of manufacturing variability. The firm modified the FDA-approved dissolution method multiple times without adequate justification. FDA analysis confirmed dissolution failures, leading to a 2017 recall of five lots by Pfizer. The firm's response regarding sample handling and delayed testing was deemed inadequate, as it didn't fully address manufacturing process variability or the quality of all in-date lots. * **Morphine Sulfate Oral Solution Leaks/Under-fills:** At least 24 complaints (July-December 2016) regarding ~1,000 leaking/under-filled bottles were initially attributed to shipping damage. A thorough investigation, initiated post-inspection, identified defective caps with cracks. The firm's response was inadequate as defective product remained on

Company
Tris Pharma Inc.
Inspection date
March 20, 2017
Product type
Drugs
Office
New Jersey District Office
People
  • Diana Amador-Toro (District Director)
  • John F. Kelly (Mr.)
View Company Profile

ID · c35be989-8a74-4f88-9f30-bc0eaa051dad

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.19221 CFR 211.100(a)21 CFR 211.3421 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Tris Pharma Inc.
  • 483 - 2025-11-21November 21, 2025
  • 483 - 2024-03-08March 8, 2024
  • 483 - 2021-06-08June 8, 2021
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Tris Pharma Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.